Kymera Therapeutics (KYMR) Cash & Current Investments (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Cash & Current Investments for 8 consecutive years, with $650.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 40.54% year-over-year to $650.9 million; the TTM figure through Mar 2026 stood at $650.9 million (up 40.54% YoY), while the FY2025 annual figure was $848.3 million, up 73.56% from the prior year.
• Cash & Current Investments retreated to $650.9 million in Q1 2026 per KYMR's latest filing, from $848.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $848.3 million in Q4 2025 and bottomed at $33.7 million in Q1 2022.
• Historically, Cash & Current Investments has averaged $452.9 million across 5 years, with a median of $481.9 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 89.89% — and 2023, when it surged 1076.52%.
• Kymera Therapeutics' Cash & Current Investments stood at $407.2 million in 2022, then slipped by 7.93% to $374.9 million in 2023, then soared by 30.37% to $488.7 million in 2024, then jumped by 73.56% to $848.3 million in 2025, then retreated by 23.26% to $650.9 million in 2026.
• Business Quant data shows KYMR's Cash & Current Investments at $650.9 million in Q1 2026, $848.3 million in Q4 2025, and $505.7 million in Q3 2025.